1415329-20-2

Basic information

• Product Name: Ald-PEG4-t-butyl ester
• Synonyms: Ald-PEG4-t-butyl ester;Ald-CH2-PEG4-CH2CH2COOtBu
• CAS NO: 1415329-20-2
• Molecular Formula: C15H28O7
• Molecular Weight: 320.37862
• Mol File: 1415329-20-2.mol

Chemical Properties

• Boiling Point: 401.7±35.0 °C(Predicted)
• Appearance: /
• Density: 1.059±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Ald-PEG4-t-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Ald-PEG4-t-butyl ester(1415329-20-2)
• EPA Substance Registry System: Ald-PEG4-t-butyl ester(1415329-20-2)

Safety Data

• Hazardous Substances Data: 1415329-20-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ald-PEG4-t-butyl ester is used as a molecular linker for the conjugation of therapeutic agents, particularly in the development of targeted drug delivery systems. Its ability to react with aminooxy-containing molecules allows for the creation of stable and specific drug conjugates, enhancing the efficacy and selectivity of the therapeutic agents.
Used in Bioconjugation:
Ald-PEG4-t-butyl ester is used as a bioconjugation agent to attach biologically active molecules, such as peptides, proteins, or nucleic acids, to other molecules or surfaces. The PEG linker provides increased solubility and stability, while the t-butyl ester group allows for controlled release and further modification under acidic conditions.
Used in Diagnostics:
In the diagnostics industry, Ald-PEG4-t-butyl ester is used as a component in the development of imaging agents and biosensors. The PEG linker can improve the pharmacokinetic properties of these agents, while the t-butyl ester group can be used for site-specific conjugation of imaging labels or detection moieties.
Used in Material Science:
Ald-PEG4-t-butyl ester is used as a building block in the synthesis of novel materials with tailored properties. The PEG linker can be incorporated into polymers, dendrimers, or other macromolecular structures to enhance their solubility, biocompatibility, and stability. Additionally, the t-butyl ester group can be used for further functionalization or crosslinking of these materials.
Used in Cosmetics and Personal Care:
In the cosmetics and personal care industry, Ald-PEG4-t-butyl ester is used as an ingredient in the formulation of skincare and haircare products. The PEG linker can improve the solubility and bioavailability of active ingredients, while the t-butyl ester group can be used for controlled release and enhanced efficacy.

Upstream product

• 1415329-18-8 C₂₈H₄₂N₄O₉ 
• 518044-32-1 tert-butyl 3-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)propanoate 
• 1663-39-4 tert-Butyl acrylate 
• 112-60-7 Tetraethylene glycol 

Downstream Products

• 1415329-21-3 C₅₆H₉₄N₆O₁₂S 

Relevant articles and documents

ANTI-CD70 ANTIBODY DRUG CONJUGATES

This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.

PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES

This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.

COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES

Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.